- Home
- FRBA vs RIGL Comparison
FRBA vs RIGL Comparison
Compare FRBA & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRBA
- RIGL
- Stock Information
- Founded
- FRBA 2007
- RIGL 1996
- Country
- FRBA United States
- RIGL United States
- Employees
- FRBA N/A
- RIGL N/A
- Industry
- FRBA Major Banks
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- FRBA Finance
- RIGL Health Care
- Exchange
- FRBA Nasdaq
- RIGL Nasdaq
- Market Cap
- FRBA 323.4M
- RIGL 335.5M
- IPO Year
- FRBA N/A
- RIGL 2000
- Fundamental
- Price
- FRBA $14.53
- RIGL $19.20
- Analyst Decision
- FRBA Buy
- RIGL Buy
- Analyst Count
- FRBA 1
- RIGL 5
- Target Price
- FRBA $17.00
- RIGL $36.40
- AVG Volume (30 Days)
- FRBA 41.1K
- RIGL 242.8K
- Earning Date
- FRBA 07-23-2025
- RIGL 05-06-2025
- Dividend Yield
- FRBA 1.65%
- RIGL N/A
- EPS Growth
- FRBA 36.40
- RIGL N/A
- EPS
- FRBA 1.54
- RIGL 2.08
- Revenue
- FRBA $128,402,000.00
- RIGL $203,077,000.00
- Revenue This Year
- FRBA $5.45
- RIGL $16.75
- Revenue Next Year
- FRBA $5.95
- RIGL $13.74
- P/E Ratio
- FRBA $9.43
- RIGL $9.21
- Revenue Growth
- FRBA 21.15
- RIGL 70.16
- 52 Week Low
- FRBA $11.20
- RIGL $7.48
- 52 Week High
- FRBA $15.87
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- FRBA 48.08
- RIGL 50.40
- Support Level
- FRBA $14.21
- RIGL $18.32
- Resistance Level
- FRBA $15.33
- RIGL $19.91
- Average True Range (ATR)
- FRBA 0.32
- RIGL 1.09
- MACD
- FRBA -0.08
- RIGL -0.04
- Stochastic Oscillator
- FRBA 27.12
- RIGL 42.12
About FRBA First Bank
First Bank is a full-service commercial bank, with target businesses from individuals, businesses, and governmental entities located in service regions throughout New Jersey and eastern Pennsylvania, with a particular focus between New York City and Philadelphia. The group focuses on traditional deposit and loan products with businesses and individuals living and working in markets as the source of businesses. Its services are Business Banking; Personal banking; Digital Banking; and Lending.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.